Sinovac vaccine ‘well tolerated, safe and induced humoral responses’ in minors aged 3-17, to boost public confidence on herd immunity
The world's first trial results on minors aged 3-17 showed China's inactivated COVID-19 vaccine produced by Sinovac had good safety, tolerability, and immunogenicity in youths aged 3-17 years, the Global…